Abstract
BackgroundDespite the benefits of immune checkpoint inhibitors (ICIs) in solid tumors, additional treatment options are needed for patients with primary or acquired resistance.1 TILs are present in various solid tumors,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
